Logo image of CDIO

CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Fundamental Analysis

USA - NASDAQ:CDIO - US14159C2026 - Common Stock

3.87 USD
+0.01 (+0.26%)
Last: 11/10/2025, 1:25:12 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CDIO. CDIO was compared to 531 industry peers in the Biotechnology industry. The financial health of CDIO is average, but there are quite some concerns on its profitability. CDIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CDIO has reported negative net income.
In the past year CDIO has reported a negative cash flow from operations.
CDIO had negative earnings in each of the past 5 years.
In the past 5 years CDIO reported 4 times negative operating cash flow.
CDIO Yearly Net Income VS EBIT VS OCF VS FCFCDIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M

1.2 Ratios

CDIO has a Return On Assets (-60.12%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -64.27%, CDIO is in line with its industry, outperforming 59.89% of the companies in the same industry.
Industry RankSector Rank
ROA -60.12%
ROE -64.27%
ROIC N/A
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
CDIO Yearly ROA, ROE, ROICCDIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CDIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDIO Yearly Profit, Operating, Gross MarginsCDIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDIO has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, CDIO has an improved debt to assets ratio.
CDIO Yearly Shares OutstandingCDIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 500K 1M 1.5M
CDIO Yearly Total Debt VS Total AssetsCDIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

CDIO has an Altman-Z score of 1.54. This is a bad value and indicates that CDIO is not financially healthy and even has some risk of bankruptcy.
CDIO has a Altman-Z score of 1.54. This is in the better half of the industry: CDIO outperforms 65.35% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CDIO is not too dependend on debt financing.
The Debt to Equity ratio of CDIO (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.54
ROIC/WACCN/A
WACC8.54%
CDIO Yearly LT Debt VS Equity VS FCFCDIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

CDIO has a Current Ratio of 23.55. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 23.55, CDIO belongs to the best of the industry, outperforming 96.61% of the companies in the same industry.
CDIO has a Quick Ratio of 23.55. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
CDIO's Quick ratio of 23.55 is amongst the best of the industry. CDIO outperforms 96.61% of its industry peers.
Industry RankSector Rank
Current Ratio 23.55
Quick Ratio 23.55
CDIO Yearly Current Assets VS Current LiabilitesCDIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

3

3. Growth

3.1 Past

CDIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
The Revenue for CDIO has decreased by -50.13% in the past year. This is quite bad
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.06%
Revenue 1Y (TTM)-50.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 2032.01% on average over the next years. This is a very strong growth
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CDIO Yearly Revenue VS EstimatesCDIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
CDIO Yearly EPS VS EstimatesCDIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CDIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CDIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDIO Price Earnings VS Forward Price EarningsCDIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDIO Per share dataCDIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CDIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIO DIAGNOSTICS HOLDINGS

NASDAQ:CDIO (11/10/2025, 1:25:12 PM)

3.87

+0.01 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14
Earnings (Next)11-11 2025-11-11
Inst Owners4.81%
Inst Owner Change7.76%
Ins Owners4.04%
Ins Owner Change0%
Market Cap6.81M
Revenue(TTM)19.50K
Net Income(TTM)-6.25M
Analysts82.86
Price Target61.2 (1481.4%)
Short Float %2.41%
Short Ratio1.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)826.47%
Min Revenue beat(2)-90.2%
Max Revenue beat(2)1743.14%
Revenue beat(4)1
Avg Revenue beat(4)369.67%
Min Revenue beat(4)-93.86%
Max Revenue beat(4)1743.14%
Revenue beat(8)1
Avg Revenue beat(8)140.84%
Revenue beat(12)1
Avg Revenue beat(12)60.85%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 349.29
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-9.9
EYN/A
EPS(NY)-7.65
Fwd EYN/A
FCF(TTM)-3.26
FCFYN/A
OCF(TTM)-3.14
OCFYN/A
SpS0.01
BVpS5.53
TBVpS5.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.12%
ROE -64.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.71%
Cap/Sales 1109.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.55
Quick Ratio 23.55
Altman-Z 1.54
F-Score4
WACC8.54%
ROIC/WACCN/A
Cap/Depr(3y)419.33%
Cap/Depr(5y)421.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.06%
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-50.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.7%
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.89%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIO DIAGNOSTICS HOLDINGS / CDIO FAQ

What is the fundamental rating for CDIO stock?

ChartMill assigns a fundamental rating of 2 / 10 to CDIO.


Can you provide the valuation status for CARDIO DIAGNOSTICS HOLDINGS?

ChartMill assigns a valuation rating of 0 / 10 to CARDIO DIAGNOSTICS HOLDINGS (CDIO). This can be considered as Overvalued.


How profitable is CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock?

CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a profitability rating of 1 / 10.


How financially healthy is CARDIO DIAGNOSTICS HOLDINGS?

The financial health rating of CARDIO DIAGNOSTICS HOLDINGS (CDIO) is 5 / 10.